Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation

Veterinary Immunology and Immunopathology

Volumn 142, Issue 1-2, 2011, Pages 101-106

  Yamada, Osamu ^a   Kobayashi, Masato ^a   Sugisaki, Osamu ^a   Ishii, Noriko ^a   Ito, Keita ^a   Kuroki, Shiori ^a   Sasaki, Yu ^a   Isotani, Mayu ^a   Ono, Kenichiro ^a,b   Washizu, Tsukimi ^a   Bonkobara, Makoto ^a  

^a NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^b Japan Animal Referral Medical Center   (Japan)

Author keywords

C kit; Dog; Imatinib; Mast cell tumor; Mutation; Target therapy

Indexed keywords

IMATINIB; PREDNISOLONE; VINBLASTINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOG; DRUG DOSE REDUCTION; DRUG RESPONSE; GENE MUTATION; GENE SEQUENCE; IN VITRO STUDY; LYMPH NODE METASTASIS; MALE; MAST CELL; MASTOCYTOMA; NONHUMAN; ONCOGENE C KIT; PHOSPHORYLATION; SEQUENCE ANALYSIS; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; MALE; MASTOCYTOMA, SKIN; PHOSPHORYLATION; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 79957940523     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2011.04.002     Document Type: Article

References (11)

1. Antonescu C.R., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., Leversha M.A., Jeffrey P.D., Desantis D., Singer S., Brennan M.F., Maki R.G., DeMatteo R.P. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 2005, 11:4182-4190.
2. Goemans B.F., Zwaan C.M., Miller M., Zimmermann M., Harlow A., Meshinchi S., Loonen A.H., Hählen K., Reinhardt D., Creutzig U., Kaspers G.J., Heinrich M.C. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005, 19:1536-1542.
3. Hahn K.A., Ogilvie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., Dubreuil P., Moussy A., Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors. J. Vet. Intern. Med. 2008, 22:1301-1309.
4. Isotani M., Ishida N., Tominaga M., Tamura K., Yagihara H., Ochi S., Kato R., Kobayashi T., Fujita M., Fujino Y., Setoguchi A., Ono K., Washizu T., Bonkobara M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J. Vet. Intern. Med. 2008, 22:985-988.
5. Isotani M., Yamada O., Lachowicz J.L., Tamura K., Yagihara H., Fujino Y., Ono K., Washizu T., Bonkobara M. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. Br. J. Haematol. 2010, 148:144-153.
6. Letard S., Yang Y., Hanssens K., Palmérini F., Leventhal P.S., Guéry S., Moussy A., Kinet J.P., Hermine O., Dubreuil P. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol. Cancer Res. 2008, 6:1137-1145.
7. London C.A., Galli S.J., Yuuki T., Hu Z.Q., Helfand S.C., Geissler E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 1999, 27:689-697.
8. London C.A., Malpas P.B., Wood-Follis S.L., Boucher J.F., Rusk A.W., Rosenberg M.P., Henry C.J., Mitchener K.L., Klein M.K., Hintermeister J.G., Bergman P.J., Couto G.C., Mauldin G.N., Michels G.M. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin. Cancer Res. 2009, 15:3856-3865.
9. Tabone-Eglinger S., Subra F., El Sayadi H., Alberti L., Tabone E., Michot J.P., Théou-Anton N., Lemoine A., Blay J.Y., Emile J.F. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin. Cancer. Res. 2008, 14:2285-2294.
10. Takeuchi Y., Fujino Y., Watanabe M., Nakagawa T., Ohno K., Sasaki N., Sugano S., Tsujimoto H. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines. Vet. Immunol. Immunopathol. 2010, 137:208-216.
11. Xiang Z., Kreisel F., Cain J., Colson A., Tomasson M.H. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol. Cell. Biol. 2007, 27:267-282.